Welcome to our dedicated page for Kura Oncology news (Ticker: KURA), a resource for investors and traders seeking the latest updates and insights on Kura Oncology stock.
Kura Oncology, Inc. (Nasdaq: KURA) is a biopharmaceutical company focused on precision medicines for cancer, and its news flow reflects the evolution of this strategy. Company announcements highlight progress with KOMZIFTI (ziftomenib), an oral menin inhibitor approved in the United States for adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible NPM1 mutation who have no satisfactory alternative treatment options.
News items for KURA commonly cover regulatory milestones, clinical data and commercial updates. Recent releases describe full FDA approval of KOMZIFTI, its addition to the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology as a Category 2A recommended option for relapsed or refractory NPM1-mutated AML, and the start of U.S. commercial sales. Kura also reports on its collaboration with Kyowa Kirin, including milestone payments tied to clinical and commercial events.
Investors following KURA news can expect detailed coverage of clinical trial readouts from programs such as KOMET-001, KOMET-007 and KOMET-017, which evaluate ziftomenib across newly diagnosed and relapsed or refractory AML, often in combination with regimens like cytarabine/daunorubicin and venetoclax/azacitidine. Additional news addresses the company’s farnesyl transferase inhibitor programs, darlifarnib and tipifarnib, and their activity in solid tumors.
Kura’s press releases also include corporate updates such as financial results, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), and participation in scientific and investor conferences. For readers tracking KURA, this news page offers a centralized view of key developments in its precision oncology pipeline, regulatory interactions, collaborations and commercialization activities.
Kura Oncology, Inc. (Nasdaq: KURA) has initiated an underwritten public offering to sell $200 million in common stock, with an option for underwriters to purchase an additional $30 million. The offering is subject to market conditions, and no assurance is given regarding its completion. The shares will be offered under a shelf registration statement filed with the SEC. The transaction will be managed by SVB Leerink, Credit Suisse, Barclays, and Stifel.
Kura Oncology announced preliminary data from its Phase 1/2A clinical trial of KO-539, an oral menin inhibitor, for treating relapsed/refractory acute myeloid leukemia (AML). Encouraging results showed evidence of biologic activity in all dose-escalation cohorts, with two complete remissions (CR) in patients with specific genetic mutations. The continuous dosing of KO-539 was well tolerated with manageable safety, and Kura plans to recommend a Phase 2 dose and advance to expansion cohorts in early 2021.
Kura Oncology will host a virtual investor event on December 5, 2020, at 2:00 p.m. ET to discuss preliminary clinical data regarding its menin inhibitor, KO-539, following its presentation at the 62nd American Society of Hematology (ASH) Annual Meeting. The event will feature Kura's management team and investigators from the ongoing KOMET-001 trial. A live video webcast will be available on Kura's website, with an archived replay accessible after the event.
Kura Oncology reported third quarter 2020 results, highlighting significant developments in its clinical pipeline and financial standing. Preliminary data from the KOMET-001 trial of KO-539, a menin inhibitor, showed promising safety and anti-leukemic activity. The drug is nearing a recommended Phase 2 dose with expansion cohorts planned for specific AML populations. Additionally, preclinical data supports the combination of tipifarnib with a PI3Kα inhibitor for treating HRAS-dependent HNSCC. Kura ended Q3 2020 with $325.4 million in cash, ensuring operational support into 2023.
Kura Oncology, Inc. (Nasdaq: KURA) announced participation in three upcoming virtual investor conferences. CEO Troy Wilson will present at the Credit Suisse 29th Annual Healthcare Conference on November 11, 2020, at 10:15 a.m. ET. CFO Marc Grasso will speak at the Stifel Virtual Healthcare Conference on November 16, 2020, at 1:20 p.m. ET. Additionally, a pre-recorded fireside chat with Dr. Wilson will be available on Kura's website during the Piper Sandler 32nd Annual Healthcare Conference from December 1-3, 2020. Live audio webcasts will also be accessible on Kura's IR website.
Kura Oncology (KURA) will release its third quarter 2020 financial results on November 5, 2020, before U.S. markets open. A conference call and webcast will follow at 8 a.m. ET to discuss the results and provide a corporate update. The company focuses on developing precision cancer treatments, with its lead candidate, tipifarnib, in a registration-directed trial for HRAS mutant head and neck cancer. Kura also has KO-539, a menin inhibitor in Phase 1/2A trials for acute myeloid leukemia.
Kura Oncology has unveiled new preclinical data supporting the use of tipifarnib in treating HRAS/PI3K-dependent tumors, which account for up to 50% of head and neck squamous cell carcinoma (HNSCC) cases. The company plans to initiate a Phase 1/2 proof-of-concept study combining tipifarnib with a PI3Kα inhibitor in relapsed/refractory HNSCC. Current estimates suggest that 20% of HNSCC patients overexpress HRAS while 35% have PIK3CA mutations. Kura's ongoing AIM-HN trial focuses on HRAS mutant HNSCC, which affects 4-8% of patients.
Kura Oncology, a clinical-stage biopharmaceutical company, announced that preliminary data from its KOMET-001 study will be presented at the 62nd ASH Annual Meeting on December 5, 2020. This ongoing trial evaluates the safety and efficacy of KO-539, an oral menin inhibitor for patients with relapsed/refractory acute myeloid leukemia (AML). Data will be available on the ASH website on November 5, 2020. The presentation aims to assess anti-leukemic activity in specific genetic subgroups, highlighting the potential of KO-539 in addressing high unmet medical needs.
Kura Oncology (Nasdaq: KURA) announced that CEO Troy Wilson will participate in two virtual investor conferences. The events include a fireside chat at the H.C. Wainwright 22nd Annual Global Investment Conference on September 15, 2020, at 11:30 a.m. ET, and another at the 2020 Cantor Virtual Global Healthcare Conference on September 16, 2020, at 4:00 p.m. ET. Live webcasts will be accessible on Kura’s website, with archived replays available for 30 days. Kura is focused on precision medicines for cancer, with drug candidates targeting critical pathways in cancer treatment.
Kura Oncology announced the appointment of Stephen Dale, M.D., as the new Chief Medical Officer. Dr. Dale brings extensive experience from his previous role at Kyowa Kirin, focusing on oncology. His leadership is expected to enhance Kura's clinical development efforts, particularly for tipifarnib in HRAS-dependent head and neck cancers and KO-539 in acute myeloid leukemia.
Former acting CMO Bridget Martell will transition to Senior Scientific Advisor, continuing her contributions to Kura's strategic initiatives.